The U.K. Competition and Markets Authority is investigating Aspen Pharmacare Holdings Ltd. for alleged anticompetitive conduct relating to the supply of blood pressure drug Fludrocortisone acetate and arthritis drug Dexamethasone, Reuters reported Oct. 13.
Aspen said in a statement that the investigation is at an early stage and the regulator has not yet reached a decision on whether competition law has been infringed, the news outlet reported.
The drugs under investigation had a combined revenue of £11.1 million in Britain in 2016.
Earlier in October, the Competition Commission of South Africa dropped its investigations into Aspen for suspected excessive pricing of certain cancer drugs. The investigation found that revenues for cancer drugs Myleran, Alkeran and Leukeran are very low as they were at the end of their lifespans.